| 摘要 |
The present invention is directed to a polynucleotide of about 10 to about 50 nucleic acid bases in length, which polynucleotide hybridizes to the gene encoding fibroblast growth factor receptor. The present invention is also directed to a pharmaceutical composition comprising the above polynucleotide dissolved or dispersed in a physiologically tolerable diluent. The present invention is further directed to a process for inhibiting vascular smooth muscle cell proliferation (figs. 1 and 2), a process for treating vascular smooth muscle cell proliferation (figs. 3 and 4), and a process for treating a disease state involving vascular smooth muscle cell proliferation (figs. 3 and 4), all of which processes comprise contacting vascular smooth muscle cells or administering an effective amount of a polynucleotide of about 10 to about 50 nucleic acid bases in length, said polynucleotide hybridizing to the gene for fibroblast growth factor receptor. |
